PDCD1 and neoplasm: The concurrent targeting of TAMs through a combination of a CSF1R inhibitor and cisplatin diminished Tregs, redirected the function of PD-1 antibodies toward CD8+ T cells, and bolstered the efficacy of antiangiogenic immunotherapy, resulting in significant tumor regression (Martinez-Usatorre et al., 2021).